Drugmakers, PBMs Oppose Insulin Pricing MDL
WASHINGTON, D.C. — The three major insulin makers and three major pharmacy benefit managers (PBMs) have told the Judicial Panel on Multidistrict Litigation that there is no need to centralize federal...To view the full article, register now.
Already a subscriber? Click here to view full article